IPN01203
/ Ipsen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2025
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
(clinicaltrials.gov)
- P1/2 | N=102 | Not yet recruiting | Sponsor: Ipsen
Checkpoint inhibition • First-in-human • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1